JP2012136519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012136519A5 JP2012136519A5 JP2012004674A JP2012004674A JP2012136519A5 JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5 JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- structures
- terminal side
- spacer polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 125000006850 spacer group Chemical group 0.000 claims 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012004674A JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006057475 | 2006-03-03 | ||
| JP2006057475 | 2006-03-03 | ||
| JP2012004674A JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Division JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012136519A JP2012136519A (ja) | 2012-07-19 |
| JP2012136519A5 true JP2012136519A5 (https=) | 2013-05-30 |
| JP5901299B2 JP5901299B2 (ja) | 2016-04-06 |
Family
ID=38459178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Expired - Fee Related JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
| JP2012004674A Expired - Fee Related JP5901299B2 (ja) | 2006-03-03 | 2012-01-13 | 生物活性を強化した抗体改変体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502861A Expired - Fee Related JP5598894B2 (ja) | 2006-03-03 | 2007-03-02 | 生物活性を強化した抗体改変体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090304715A1 (https=) |
| EP (2) | EP2006305B1 (https=) |
| JP (2) | JP5598894B2 (https=) |
| CA (1) | CA2638804C (https=) |
| ES (1) | ES2602439T3 (https=) |
| WO (1) | WO2007100083A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| WO2010065578A2 (en) * | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
| WO2012002562A1 (en) * | 2010-06-30 | 2012-01-05 | Tokyo University Of Science Educational Foundation Administrative Organization | Modified protein therapeutics |
| WO2012016073A2 (en) | 2010-07-28 | 2012-02-02 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価抗原結合タンパク質 |
| WO2012116926A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| JP2015527366A (ja) * | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| WO2014115893A1 (ja) | 2013-01-28 | 2014-07-31 | 株式会社イーベック | ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片 |
| WO2015005960A1 (en) | 2013-07-12 | 2015-01-15 | Emd Millipore Corporation | Removal of fragments from a sample containing a target protein using activated carbon |
| ES2935274T3 (es) * | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| LT3325011T (lt) | 2015-07-24 | 2021-01-25 | Gliknik Inc. | Iš žmogaus baltymo fragmentų sulieti baltymai, siekiant sukurti tvarkingai multimerizuoto imunoglobulino fc kompozicijas su padidintu komplemento surišimu |
| US11466093B2 (en) | 2015-07-27 | 2022-10-11 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| WO2017214321A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| CA3043251A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| CN110177802A (zh) | 2016-12-09 | 2019-08-27 | 格利克尼克股份有限公司 | 多聚化stradomer GL-2045的制造优化 |
| RU2019124709A (ru) * | 2017-01-06 | 2021-02-08 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА |
| BR112021000391A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4 |
| CN119421953A (zh) | 2022-01-28 | 2025-02-11 | 株式会社伊贝克 | 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
| DE3908834A1 (de) | 1989-03-17 | 1990-09-20 | Hollingsworth Gmbh | Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde |
| US7511121B2 (en) * | 2001-03-09 | 2009-03-31 | Arnason Barry G W | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
| WO2004029207A2 (en) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| PL1706428T3 (pl) * | 2004-01-22 | 2010-02-26 | Merck Patent Gmbh | Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza |
| WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
-
2007
- 2007-03-02 US US12/281,437 patent/US20090304715A1/en not_active Abandoned
- 2007-03-02 EP EP07737666.3A patent/EP2006305B1/en not_active Not-in-force
- 2007-03-02 CA CA2638804A patent/CA2638804C/en not_active Expired - Fee Related
- 2007-03-02 JP JP2008502861A patent/JP5598894B2/ja not_active Expired - Fee Related
- 2007-03-02 WO PCT/JP2007/054018 patent/WO2007100083A1/ja not_active Ceased
- 2007-03-02 ES ES07737666.3T patent/ES2602439T3/es active Active
- 2007-03-02 EP EP13001539.9A patent/EP2610268A1/en not_active Withdrawn
-
2012
- 2012-01-13 JP JP2012004674A patent/JP5901299B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-12 US US16/538,482 patent/US20190367630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012136519A5 (https=) | ||
| PH12013502568B1 (en) | Anti-psgl-1 antibodies and uses thereof | |
| JP2012116856A5 (https=) | ||
| SG10201909806SA (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| JP2016527273A5 (https=) | ||
| JP2013538057A5 (https=) | ||
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| JP2014526898A5 (https=) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| JP2014205674A5 (https=) | ||
| JP2012254083A5 (https=) | ||
| JP2012034692A5 (https=) | ||
| NZ748976A (en) | Bispecific binding proteins and uses thereof | |
| HRP20201600T1 (hr) | Anti-pd-1 antitijelo i njegova uporaba | |
| JP2020503891A5 (https=) | ||
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| WO2013095738A3 (en) | Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins | |
| AR085383A1 (es) | Anticuerpos contra el il33r humano y usos de los mismos | |
| HRP20161298T1 (hr) | Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba | |
| JP2014240385A5 (https=) | ||
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX2022007107A (es) | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. |